Sanofi Signs Up to $1.2 Billion Research, Exclusive License Deal with US-based Seawolf Therapeutics

MT Newswires · 2d ago
05:39 AM EST, 11/16/2026 (MT Newswires) -- Sanofi (SAN.PA) signed a multi-target research collaboration and exclusive license agreement with US-based biotechnology company Seawolf Therapeutics. Under the deal, the partners will develop undisclosed therapies for bleeding disorders and additional unnamed indications, according to a Monday release. Up to $1.2 billion in milestones and tiered royalties on sales are expected.